A Cross-sectional Investigational Study to Evaluate the Sensitivity, Specificity, and Utility of the MedMira Inc. Multiplo® Complete Syphilis (TP/nTP) Antibody Test (POCT) to Diagnose Infectious Syphilis in Participants Attending the Sexual Health Clinic in Ottawa, Ontario.

计划入组 1,300 人 · 首次发布于 2024 年 9 月 19 日

Multiplo Tp/HIV Self-Test

计划入组 900 人 · 首次发布于 2024 年 12 月 4 日

Evaluation of the Sensitivity, Specificity, and Utility of the Reveal® TP (Syphilis) Antibody POCT

计划入组 600 人 · 首次发布于 2023 年 4 月 26 日

Hypromellose(Bion Tears, Clear Eyes Complete, Genteal, Genteal Tears, Genteal Tears Mild, Gonak, Goniovisc, Isopto Alkaline, Nature's Tears, Systane, Tears Lubricant, Tears Naturale, Tears Renewed)

NTP-2014

NTP-6009

NTP Radioisotopes

Belgium

Cambridge Antibody Technology

New Zealand

LIVZON PHARMA

China

MedMira Secures Health Canada Approval for HIV/Syphilis Test Amid Regulatory Progress

MedMira's Reveal® G4 HIV-1/2 Rapid Test Achieves 100% Specificity in Clinical Trials; Awaits CLIA Waiver

MedMira's Reveal G4 Rapid HIV-1/2 Test Approved by Health Canada for Point-of-Care Use